initiated phase 3 study in asthma  report results from phase 3 atopic dermatitis pivotal trials  presented positive pivotal phase 2b data in asthma at the american thoracic society 2015 international conference  complete rolling bla submission for atopic dermatitis in the united states  completed patient enrollment in phase 3 atopic dermatitis pivotal trials  initiate efficacy and safety studies in pediatric patients in both atopic dermatitis and asthma  fda granted breakthrough therapy designation to dupilumab in atopic dermatitis  uk mhra granted pim designation to dupilumab in atopic dermatitis 61 antibody-based clinical programs ( continued ) : 2015 and 2016 events to date 2016 plans regn2222 ( rsv-f antibody )  completed phase 1 study  continue patient enrollment in phase 3 nursery pre-term study  initiated phase 3 nursery pre-term study  received fast track designation from the fda for the prevention of serious lower respiratory tract disease caused by rsv fasinumab ( ngf antibody )  initiated sixteen-week phase 2b/3 study in osteoarthritis  report results from phase 2b/3 study in osteoarthritis  completed patient enrollment in a phase 2b/3 study in osteoarthritis  initiate longer duration phase 3 trial evinacumab ( angptl-3 antibody )  initiated phase 2 study  complete patient enrollment in phase 1 and phase 2 studies  partial clinical hold lifted by the fda regn1033 ( gdf8 antibody )  phase 2 proof-of-concept study in elderly men and women with sarcopenia met its primary endpoint , while secondary , functional endpoints were mixed .  develop combination therapy plans  sanofi elected not to continue co-development regn1908-1909 ( feld1 antibody )  completed patient enrollment in phase 1/phase 2 study regn2176-3 ( pdgfr-beta antibody co-formulated with aflibercept )  received fast track designation from the fda for the treatment of patients with wet amd  continue patient enrollment in phase 2 study  initiated phase 2 study regn1979 ( cd20 and cd3 antibody )  continued patient enrollment in phase 1 study  complete patient enrollment in phase 1 study nesvacumab/aflibercept ( ang2 antibody co-formulated with aflibercept )  completed patient enrollment in phase 1 study  initiate phase 2 study regn2810 ( pd-1 antibody )  initiated phase 1 study  continue patient enrollment in phase 1 study  initiate later-stage pivotal studies 62 developing and commercializing new medicines entails significant risk and expense . before significant revenues from the commercialization of our antibody candidates or new indications for our marketed products can be realized , we ( or our collaborators ) must overcome a number of hurdles which include successfully completing research and development and obtaining regulatory approval from the fda and regulatory authorities in other countries . in addition , the biotechnology and pharmaceutical industries are rapidly evolving and highly competitive , and new developments may render our products and technologies uncompetitive or obsolete . our ability to continue to generate profits and to generate positive cash flow from operations over the next several years depends significantly on our continued success in commercializing eylea . we expect to continue to incur substantial expenses related to our research and development activities , a significant portion of which we expect to be reimbursed by our collaborators . also , our research and development activities outside our collaborations , the costs of which are not reimbursed , are expected to expand and require additional resources . we also expect to incur substantial costs related to the commercialization of praluent and preparation for potential commercialization of our late-stage antibody product candidates , approximately half of which we expect to be reimbursed by sanofi under the companies ' collaboration agreement . our financial results may fluctuate from quarter to quarter and will depend on , among other factors , the net sales of our marketed products , the scope and progress of our research and development efforts , the timing of certain expenses , the continuation of our collaborations , in particular with sanofi and bayer healthcare , including our share of collaboration profits or losses from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators , and the amount of income tax expense we incur , which is partly dependent on the profits or losses we earn in each of the countries in which we operate . we can not predict whether or when new products or new indications for marketed products will receive regulatory approval or , if any such approval is received , whether we will be able to successfully commercialize such product ( s ) and whether or when they may become profitable . critical accounting policies and use of estimates a summary of the significant accounting policies that impact us is provided in note 1 to our consolidated financial statements . the preparation of financial statements in accordance with accounting principles generally accepted in the united states of america ( gaap ) requires management to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements . management considers an accounting estimate to be critical if : it requires an assumption ( or assumptions ) regarding a future outcome ; and changes in the estimate or the use of different assumptions to prepare the estimate could have a material effect on our results of operations or financial condition . management believes the current assumptions used to estimate amounts reflected in our consolidated financial statements are appropriate . however , if actual experience differs from the assumptions used in estimating amounts reflected in our consolidated financial statements , the resulting changes could have a material adverse effect on our results of operations , and in certain situations , could have a material adverse effect on our liquidity and financial condition . the critical accounting estimates that impact our consolidated financial statements are described below . revenue recognition product revenue product sales consist of u.s. sales of eylea and arcalyst . story_separator_special_tag as of december 31 , 2015 , $ 600.0 million of the up-front payments was deferred and will be recognized ratably as revenue in future periods . in september 2003 , we and sanofi entered into a zaltrap collaboration agreement to jointly develop and commercialize zaltrap . under the terms of the zaltrap collaboration agreement , we and sanofi shared profits and losses on sales of 68 zaltrap outside of japan , and we were entitled to receive a percentage of sales of zaltrap in japan . our share of the loss in connection with the commercialization of zaltrap in 2014 represents our share of the costs of commercializing zaltrap , partly offset by net product sales . as described above in part i , item 1 . `` collaboration agreements - collaborations with sanofi - zaltrap `` , in february 2015 , we entered into an amended zaltrap agreement with sanofi which amended and restated the zaltrap collaboration agreement . as a result , in the first quarter of 2015 we recognized $ 14.9 million of previously deferred revenue under the zaltrap collaboration agreement , related to ( i ) amounts that were previously reimbursed by sanofi for manufacturing commercial supplies of zaltrap since our risk of inventory loss under the collaboration no longer existed , and ( ii ) the unamortized portion of up-front payments from sanofi as we had no further performance obligations . bayer healthcare collaboration revenue the collaboration revenue we earned from bayer healthcare , as detailed below , primarily consisted of recognition of our share of profits in connection with commercialization of eylea outside the united states , and recognition of sales milestones achieved . replace_table_token_8_th bayer healthcare commenced sales of eylea outside the united states for the treatment of wet amd in 2012 , macular edema secondary to crvo in 2013 , visual impairment due to dme in the third quarter of 2014 , mcnv ( in japan ) in the fourth quarter of 2014 , and macular edema following brvo in the second quarter of 2015. regeneron 's net profit in connection with commercialization of eylea outside the united states is summarized below . regeneron 's net profit from eylea sales outside the united states year ended december 31 , ( in millions ) 2015 2014 net product sales outside the united states $ 1,413.3 $ 1,038.5 regeneron 's share of collaboration profit from sales outside the united states 521.8 358.3 reimbursement of eylea development expenses incurred by bayer healthcare in accordance with regeneron 's payment obligation ( 55.1 ) ( 57.0 ) regeneron 's net profit in connection with commercialization of eylea outside the united states $ 466.7 $ 301.3 bayer healthcare records revenue from sales of eylea outside the united states . in 2015 and 2014 , our share of the profit we earned from commercialization of eylea outside the united states was partly offset by our contractual obligation to reimburse bayer healthcare for a portion of the agreed-upon development expenses previously incurred by bayer healthcare . 69 in 2015 , we earned our final $ 15.0 million sales milestone from bayer healthcare , upon total aggregate net sales of specific commercial supplies of eylea outside the united states exceeding $ 200 million over a twelve-month period . in 2014 , we earned seven $ 15.0 million sales milestones from bayer healthcare upon total aggregate net sales of eylea outside the united states achieving certain specified levels . cost-sharing of our global eylea development expenses with bayer healthcare decreased in 2015 compared to 2014. in january 2014 , bayer healthcare decided to participate in the global development and commercialization of eylea outside the united states for the treatment of macular edema following brvo . in connection with this decision , bayer healthcare reimbursed us $ 15.7 million for a defined share of the eylea global development costs that we had incurred prior to february 2014 for the brvo indication , which was recognized as bayer healthcare collaboration revenue in the first quarter of 2014. in addition , all future agreed-upon global eylea development expenses incurred in connection with brvo are shared equally , and any future profits or losses on sales of eylea outside of the united states for the treatment of macular edema following brvo are also shared ( for countries other than japan ; we are entitled to receive a tiered percentage of eylea net sales in japan ) . other eylea revenue primarily consists of reimbursement of other regeneron eylea expenses , principally related to bayer healthcare 's share of royalties payable to genentech pursuant to a license and settlement agreement in connection with sales of eylea outside the united states and reimbursements for producing eylea commercial supplies for bayer healthcare . in addition , other eylea revenue includes recognition of deferred revenue related to eylea up-front and 2007 non-substantive milestone payments from bayer healthcare . as of december 31 , 2015 , $ 11.1 million of the eylea up-front and 2007 milestone payments was deferred and will be recognized ratably as revenue in future periods . cost-sharing of regn2176-3 development expenses with bayer healthcare commenced in the first quarter of 2014 following the execution of the companies ' pdgfr-beta antibody collaboration agreement . other pdgfr-beta antibody revenue consists of recognition of deferred revenue related to the pdgfr-beta up-front payment and non-substantive milestones received in the first quarter of 2014. as of december 31 , 2015 , $ 9.5 million of the pdgfr-beta up-front and 2014 milestone payments was deferred and will be recognized ratably as revenue in future periods . other revenue in connection with the amendment and extension of our velocimmune license agreement with astellas , in august 2010 , we received a $ 165.0 million up-front payment , which was deferred upon receipt and is being recognized as revenue ratably over a seven-year period beginning in june 2011. in both 2015 and 2014 , we recognized $ 23.6 million of revenue related to this

net cash provided by operating activities was $ 1,330.8 million in 2015. our net income of $ 636.1 million in 2015 included non-cash compensation expense of $ 459.0 million and depreciation and amortization of $ 74.9 million . in addition , deferred tax assets as of december 31 , 2015 increased by $ 121.6 million , compared to december 31 , 2014 , primarily due to an increase in non-cash compensation expense , partly offset by a reduction in our deferred tax assets related to fixed assets and deferred revenue . as of december 31 , 2015 , sanofi , bayer healthcare , and trade accounts receivable increased by $ 491.4 million , compared to december 31 , 2014 , primarily due to higher u.s. eylea sales . inventories as of december 31 , 2015 increased by $ 111.8 million , compared to december 31 , 2014 , primarily due to increased production of eylea commercial supplies as well as capitalization of inventory in connection with praluent production . prepaid expenses and other assets increased by $ 79.5 million as of december 31 , 2015 , compared to december 31 , 2014 , primarily due to an increase in prepaid income taxes .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash provided by operating activities was $ 1,330.8 million in 2015. our net income of $ 636.1 million in 2015 included non-cash compensation expense of $ 459.0 million and depreciation and amortization of $ 74.9 million . in addition , deferred tax assets as of december 31 , 2015 increased by $ 121.6 million , compared to december 31 , 2014 , primarily due to an increase in non-cash compensation expense , partly offset by a reduction in our deferred tax assets related to fixed assets and deferred revenue . as of december 31 , 2015 , sanofi , bayer healthcare , and trade accounts receivable increased by $ 491.4 million , compared to december 31 , 2014 , primarily due to higher u.s. eylea sales . inventories as of december 31 , 2015 increased by $ 111.8 million , compared to december 31 , 2014 , primarily due to increased production of eylea commercial supplies as well as capitalization of inventory in connection with praluent production . prepaid expenses and other assets increased by $ 79.5 million as of december 31 , 2015 , compared to december 31 , 2014 , primarily due to an increase in prepaid income taxes .
```    
 Suspicious Activity Report : initiated phase 3 study in asthma  report results from phase 3 atopic dermatitis pivotal trials  presented positive pivotal phase 2b data in asthma at the american thoracic society 2015 international conference  complete rolling bla submission for atopic dermatitis in the united states  completed patient enrollment in phase 3 atopic dermatitis pivotal trials  initiate efficacy and safety studies in pediatric patients in both atopic dermatitis and asthma  fda granted breakthrough therapy designation to dupilumab in atopic dermatitis  uk mhra granted pim designation to dupilumab in atopic dermatitis 61 antibody-based clinical programs ( continued ) : 2015 and 2016 events to date 2016 plans regn2222 ( rsv-f antibody )  completed phase 1 study  continue patient enrollment in phase 3 nursery pre-term study  initiated phase 3 nursery pre-term study  received fast track designation from the fda for the prevention of serious lower respiratory tract disease caused by rsv fasinumab ( ngf antibody )  initiated sixteen-week phase 2b/3 study in osteoarthritis  report results from phase 2b/3 study in osteoarthritis  completed patient enrollment in a phase 2b/3 study in osteoarthritis  initiate longer duration phase 3 trial evinacumab ( angptl-3 antibody )  initiated phase 2 study  complete patient enrollment in phase 1 and phase 2 studies  partial clinical hold lifted by the fda regn1033 ( gdf8 antibody )  phase 2 proof-of-concept study in elderly men and women with sarcopenia met its primary endpoint , while secondary , functional endpoints were mixed .  develop combination therapy plans  sanofi elected not to continue co-development regn1908-1909 ( feld1 antibody )  completed patient enrollment in phase 1/phase 2 study regn2176-3 ( pdgfr-beta antibody co-formulated with aflibercept )  received fast track designation from the fda for the treatment of patients with wet amd  continue patient enrollment in phase 2 study  initiated phase 2 study regn1979 ( cd20 and cd3 antibody )  continued patient enrollment in phase 1 study  complete patient enrollment in phase 1 study nesvacumab/aflibercept ( ang2 antibody co-formulated with aflibercept )  completed patient enrollment in phase 1 study  initiate phase 2 study regn2810 ( pd-1 antibody )  initiated phase 1 study  continue patient enrollment in phase 1 study  initiate later-stage pivotal studies 62 developing and commercializing new medicines entails significant risk and expense . before significant revenues from the commercialization of our antibody candidates or new indications for our marketed products can be realized , we ( or our collaborators ) must overcome a number of hurdles which include successfully completing research and development and obtaining regulatory approval from the fda and regulatory authorities in other countries . in addition , the biotechnology and pharmaceutical industries are rapidly evolving and highly competitive , and new developments may render our products and technologies uncompetitive or obsolete . our ability to continue to generate profits and to generate positive cash flow from operations over the next several years depends significantly on our continued success in commercializing eylea . we expect to continue to incur substantial expenses related to our research and development activities , a significant portion of which we expect to be reimbursed by our collaborators . also , our research and development activities outside our collaborations , the costs of which are not reimbursed , are expected to expand and require additional resources . we also expect to incur substantial costs related to the commercialization of praluent and preparation for potential commercialization of our late-stage antibody product candidates , approximately half of which we expect to be reimbursed by sanofi under the companies ' collaboration agreement . our financial results may fluctuate from quarter to quarter and will depend on , among other factors , the net sales of our marketed products , the scope and progress of our research and development efforts , the timing of certain expenses , the continuation of our collaborations , in particular with sanofi and bayer healthcare , including our share of collaboration profits or losses from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators , and the amount of income tax expense we incur , which is partly dependent on the profits or losses we earn in each of the countries in which we operate . we can not predict whether or when new products or new indications for marketed products will receive regulatory approval or , if any such approval is received , whether we will be able to successfully commercialize such product ( s ) and whether or when they may become profitable . critical accounting policies and use of estimates a summary of the significant accounting policies that impact us is provided in note 1 to our consolidated financial statements . the preparation of financial statements in accordance with accounting principles generally accepted in the united states of america ( gaap ) requires management to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements . management considers an accounting estimate to be critical if : it requires an assumption ( or assumptions ) regarding a future outcome ; and changes in the estimate or the use of different assumptions to prepare the estimate could have a material effect on our results of operations or financial condition . management believes the current assumptions used to estimate amounts reflected in our consolidated financial statements are appropriate . however , if actual experience differs from the assumptions used in estimating amounts reflected in our consolidated financial statements , the resulting changes could have a material adverse effect on our results of operations , and in certain situations , could have a material adverse effect on our liquidity and financial condition . the critical accounting estimates that impact our consolidated financial statements are described below . revenue recognition product revenue product sales consist of u.s. sales of eylea and arcalyst . story_separator_special_tag as of december 31 , 2015 , $ 600.0 million of the up-front payments was deferred and will be recognized ratably as revenue in future periods . in september 2003 , we and sanofi entered into a zaltrap collaboration agreement to jointly develop and commercialize zaltrap . under the terms of the zaltrap collaboration agreement , we and sanofi shared profits and losses on sales of 68 zaltrap outside of japan , and we were entitled to receive a percentage of sales of zaltrap in japan . our share of the loss in connection with the commercialization of zaltrap in 2014 represents our share of the costs of commercializing zaltrap , partly offset by net product sales . as described above in part i , item 1 . `` collaboration agreements - collaborations with sanofi - zaltrap `` , in february 2015 , we entered into an amended zaltrap agreement with sanofi which amended and restated the zaltrap collaboration agreement . as a result , in the first quarter of 2015 we recognized $ 14.9 million of previously deferred revenue under the zaltrap collaboration agreement , related to ( i ) amounts that were previously reimbursed by sanofi for manufacturing commercial supplies of zaltrap since our risk of inventory loss under the collaboration no longer existed , and ( ii ) the unamortized portion of up-front payments from sanofi as we had no further performance obligations . bayer healthcare collaboration revenue the collaboration revenue we earned from bayer healthcare , as detailed below , primarily consisted of recognition of our share of profits in connection with commercialization of eylea outside the united states , and recognition of sales milestones achieved . replace_table_token_8_th bayer healthcare commenced sales of eylea outside the united states for the treatment of wet amd in 2012 , macular edema secondary to crvo in 2013 , visual impairment due to dme in the third quarter of 2014 , mcnv ( in japan ) in the fourth quarter of 2014 , and macular edema following brvo in the second quarter of 2015. regeneron 's net profit in connection with commercialization of eylea outside the united states is summarized below . regeneron 's net profit from eylea sales outside the united states year ended december 31 , ( in millions ) 2015 2014 net product sales outside the united states $ 1,413.3 $ 1,038.5 regeneron 's share of collaboration profit from sales outside the united states 521.8 358.3 reimbursement of eylea development expenses incurred by bayer healthcare in accordance with regeneron 's payment obligation ( 55.1 ) ( 57.0 ) regeneron 's net profit in connection with commercialization of eylea outside the united states $ 466.7 $ 301.3 bayer healthcare records revenue from sales of eylea outside the united states . in 2015 and 2014 , our share of the profit we earned from commercialization of eylea outside the united states was partly offset by our contractual obligation to reimburse bayer healthcare for a portion of the agreed-upon development expenses previously incurred by bayer healthcare . 69 in 2015 , we earned our final $ 15.0 million sales milestone from bayer healthcare , upon total aggregate net sales of specific commercial supplies of eylea outside the united states exceeding $ 200 million over a twelve-month period . in 2014 , we earned seven $ 15.0 million sales milestones from bayer healthcare upon total aggregate net sales of eylea outside the united states achieving certain specified levels . cost-sharing of our global eylea development expenses with bayer healthcare decreased in 2015 compared to 2014. in january 2014 , bayer healthcare decided to participate in the global development and commercialization of eylea outside the united states for the treatment of macular edema following brvo . in connection with this decision , bayer healthcare reimbursed us $ 15.7 million for a defined share of the eylea global development costs that we had incurred prior to february 2014 for the brvo indication , which was recognized as bayer healthcare collaboration revenue in the first quarter of 2014. in addition , all future agreed-upon global eylea development expenses incurred in connection with brvo are shared equally , and any future profits or losses on sales of eylea outside of the united states for the treatment of macular edema following brvo are also shared ( for countries other than japan ; we are entitled to receive a tiered percentage of eylea net sales in japan ) . other eylea revenue primarily consists of reimbursement of other regeneron eylea expenses , principally related to bayer healthcare 's share of royalties payable to genentech pursuant to a license and settlement agreement in connection with sales of eylea outside the united states and reimbursements for producing eylea commercial supplies for bayer healthcare . in addition , other eylea revenue includes recognition of deferred revenue related to eylea up-front and 2007 non-substantive milestone payments from bayer healthcare . as of december 31 , 2015 , $ 11.1 million of the eylea up-front and 2007 milestone payments was deferred and will be recognized ratably as revenue in future periods . cost-sharing of regn2176-3 development expenses with bayer healthcare commenced in the first quarter of 2014 following the execution of the companies ' pdgfr-beta antibody collaboration agreement . other pdgfr-beta antibody revenue consists of recognition of deferred revenue related to the pdgfr-beta up-front payment and non-substantive milestones received in the first quarter of 2014. as of december 31 , 2015 , $ 9.5 million of the pdgfr-beta up-front and 2014 milestone payments was deferred and will be recognized ratably as revenue in future periods . other revenue in connection with the amendment and extension of our velocimmune license agreement with astellas , in august 2010 , we received a $ 165.0 million up-front payment , which was deferred upon receipt and is being recognized as revenue ratably over a seven-year period beginning in june 2011. in both 2015 and 2014 , we recognized $ 23.6 million of revenue related to this

